Algenex has more than 20 years’ experience in the veterinary sector and is focused on developing and producing veterinary vaccines using its TopBac® and CrisBio® technology platforms.

We have successfully produced more than 200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies and achieved proof-of- concept in more than 20 indications across most livestock species.

The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by the European Medicines Agency (EMA) with potential approval in 2021.

Benefits of using CrisBio® in the production of proteins for veterinary vaccines:

  • Linear scalability

  • Reduced production costs

  • Increased productivity, reaching gram per litre yields

Most advanced projects

RHDV

PCV2

BVD

INFLUENZA

H7N9

African Swine Fever

AB rapid detection test

Partnerships

Algenex has a long track record of successful collaborations with public and private partners on a global scale. Customer satisfaction is one of our top priorities

For us, CrisBio® technology represents an important opportunity to expand its portfolio of vaccines for veterinary use with a series of highly innovative products

Francesco Meliotta

Vicepresident responsible for IVMPs at Fatro SpA

DIAGNOSTICS

Algenex has developed the Herdscreen® ASFV Antibody Test for African Swine Fever in collaboration with Global Dx.

Analysis of the new rapid test at the European Union Reference Laboratory for African swine fever (CISA-INIA) showed 100% specificity and higher sensitivity than a commercial ELISA test for the detection of specific antibodies in field and experimental samples from infected animals.

This new pen-side diagnostic test for African Swine Fever will be commercially available in 2020.